Get back to being the insurer of choice for individuals and groups. Contract for the services you need, not own them and try to manage them too. UHG would not be the first insurer who has faced ...

Your Editor recommends grabbing lunch or a cuppa for these lengthy reads/views: Flawed Federal Programs Maroon Rural Americans in Telehealth Blackouts. This is mostly about the billions spent in ‘last ...

One of our Perspectives contributors, Yosi Health, is seeking a Demand Generation Manager for their B2B buyer customers. This role combines lead generation with marketing analysis, coordination with ...

Leading our news with a short, heartwarming story. The White House’s proposed discretionary budget for FY 2026 calls for an increase of nearly $2.2 billion in funding for the EHR program as a “top ...

More on this in Strata-gee 15 May. More good news– Editor Ted Green is recuperating and back at his desk, if only part-time. He has been invaluable for his inside looks at Masimo’s endless drama over ...

Hinge Health now public. Today (22 May) Hinge Health debuts as HNGE on the NYSE, the first big IPO for healthcare tech in two years. Last night, the virtual MSK/physical therapy provider raised $437.3 ...

The major news this week was the Hinge Health IPO, the first for digital health in two years–but the downside was that it was at a lower valuation. Denouements abounded with most 23andMe genetic ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

The major news this week was the Hinge Health IPO, the first for digital health in two years–but the downside was that it was at a lower valuation. Denouements abounded with most 23andMe genetic ...

Transcarent closes Accolade buy, changes its game. Transcarent’s $621 million acquisition of Accolade was wrapped up in record time (two months from announcement). This takes the Nasdaq-listed ...